Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2020 at "Future cardiology"
DOI: 10.2217/fca-2020-0017
Abstract: Apabetalone is the first selective BET protein inhibitor in the field of cardiovascular diseases (CVD). BET proteins are epigenetic regulators that link upstream epigenetic modifications to downstream gene expression. Inhibition of BET proteins by apabetalone has… read more here.
Keywords: inhibition cardiovascular; apabetalone bet; bet protein; protein inhibition ... See more keywords